Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Universal Ibogaine Inc: Universal Ibogaine hires Changemark to help with CTA | 2 | Stockwatch | ||
Mo | Universal Ibogaine Inc.: Universal Ibogaine provides update on planned Clinical Trial Application process | 2 | TheNewswire | ||
22.04. | Universal Ibogaine Inc: Universal Ibogaine arranges $350,000 private placement | 2 | Stockwatch | ||
22.04. | Universal Ibogaine Inc.: Universal Ibogaine Announces Private Placement Financing and the Results of the Annual Meeting of Shareholders | 2 | TheNewswire | ||
18.04. | Universal Ibogaine Inc: Universal Ibogaine 57,557,600-share private placement | 3 | Stockwatch | ||
12.04. | Universal Ibogaine Inc: Universal Ibogaine arranges $600,000 private placement | 3 | Stockwatch | ||
12.04. | Universal Ibogaine Inc.: Universal Ibogaine announces new private placement financing | 1 | TheNewswire | ||
10.04. | Universal Ibogaine Inc: Universal Ibogaine closes $575,576 private placement | 3 | Stockwatch | ||
09.04. | Universal Ibogaine Inc: Universal Ibogaine chief clinics officer Rabb departs | 2 | Stockwatch | ||
22.02. | Universal Ibogaine Inc: Universal Ibogaine arranges $800,000 private placement | 13 | Stockwatch | ||
13.02. | Universal Ibogaine Inc: Universal Ibogaine 41,719,250-share private placement | 5 | Stockwatch | ||
07.02. | Universal Ibogaine Inc: Universal Ibogaine closes $417,192 private placement | 1 | Stockwatch | ||
02.02. | Universal Ibogaine Inc: Universal Ibogaine files fiscal 2023 financials | 4 | Stockwatch | ||
19.01. | Universal Ibogaine Inc: Universal Ibogaine expects 2023 audit finish by Jan. 24 | 5 | Stockwatch | ||
06.01. | Universal Ibogaine Inc: Universal Ibogaine working to file FY 2023, Q1 results | 5 | Stockwatch | ||
21.12.23 | Universal Ibogaine Inc: Universal Ibogaine appoints MNP as auditor | 5 | Stockwatch | ||
11.12.23 | Universal Ibogaine Inc: Universal Ibogaine receives MCTO from ASC | 3 | Stockwatch | ||
02.12.23 | Universal Ibogaine Inc: Universal Ibogaine misses results filing deadline | 5 | Stockwatch |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SANOFI | 91,49 | +0,04 % | BERNSTEIN RESEARCH stuft SANOFI auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat das Kursziel für Sanofi von 108 auf 114 Euro angehoben und die Einstufung auf "Outperform" belassen. Der Pharmakonzern habe im... ► Artikel lesen | |
CANOPY GROWTH | 7,850 | +0,77 % | Spotlight on Canopy Growth: Analyzing the Surge in Options Activity | ||
ASTRAZENECA | 141,30 | +0,71 % | JPMORGAN stuft ASTRAZENECA auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Astrazeneca vor den am 25. April erwarteten Quartalszahlen auf "Overweight" mit einem Kursziel von 13000 Pence belassen. Er liege mit Blick auf... ► Artikel lesen | |
INNOCAN PHARMA | 0,196 | +0,26 % | Innocan Pharma leitet FDA-Zulassungsverfahren für Liposomen-Injektionstherapie gegen chronische Schmerzen ein | Mit der Übermittlung eines Antragsschreibens für ein Pre-IND-Meeting leitet Innocan das behördliche Zulassungsverfahren für seine Technologie der verzögerten
CBD-Freisetzung beim Menschen bei... ► Artikel lesen | |
IONIS PHARMACEUTICALS | 38,760 | -1,02 % | Ionis Pharmaceuticals, Inc.: Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome | - Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis events -
-... ► Artikel lesen | |
HAPPY BELLY FOOD GROUP | 0,260 | 0,00 % | Happy Belly Food Group Inc.: Happy Belly Closes Acquisition of CraveIT Restaurant Group's Via Cibo Restaurant Chain | Toronto, Ontario--(Newsfile Corp. - April 24, 2024) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: VGANF) ("Happy Belly" or the "Company"), a leading consolidator of emerging food brands is pleased... ► Artikel lesen | |
CSPC PHARMA | 0,765 | -5,72 % | CSPC PHARMA's US Clinical Trial Application for Highly Selective MAT2A Inhibitor Approved | ||
ALTIMMUNE | 5,802 | -2,73 % | Guggenheim downgrades Altimmune as 'ship has likely sailed' for obesity drug | ||
AVADEL PHARMACEUTICALS | 16,900 | +0,72 % | AVADEL PHARMACEUTICALS PLC - 10-K/A, Annual Report | ||
NUMINUS WELLNESS | 0,050 | +0,60 % | Numinus Wellness Inc.: Cedar Clinical Research selected as clinical research site for Cybin's Phase 3 Study of CYB003 | VANCOUVER, BC, April 17, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral... ► Artikel lesen | |
CATALYST PHARMACEUTICALS | 14,095 | -0,74 % | Santhera Pharmaceuticals Holding AG: Santhera's Partner Catalyst Pharmaceuticals lanciert AGAMREE® (Vamorolon) in den Vereinigten Staaten | AGAMREE® ist von der U.S. FDA zugelassen und jetzt in den USA für die Behandlung von Duchenne-Muskeldystrophie (DMD) bei Patienten ab 2 Jahren erhältlichDies folgt auf die erste kommerzielle Einführung... ► Artikel lesen | |
ROCKET LAB USA | 3,520 | -0,85 % | Rocket Lab USA prepares Electron launches to deploy NASA's PREFIRE mission | ||
ONO PHARMACEUTICAL | 13,400 | 0,00 % | Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion | WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve... ► Artikel lesen | |
ELANCO ANIMAL HEALTH | 12,512 | -1,12 % | Elanco's 'Parvo is Poop' Campaign Unleashes Awareness and Action on National Parvo Awareness Day | Launches first-ever tracking site for often-fatal parvovirus outbreaks to Save 1 Million Puppies by 2030GREENFIELD, IN / ACCESSWIRE / April 23, 2024 / Elanco Animal Health Incorporated (NYSE:ELAN) today... ► Artikel lesen | |
QUALIGEN THERAPEUTICS | 0,236 | +1,72 % | Marizyme Inc.: Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft | JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the "Agreement") with Qualigen Therapeutics... ► Artikel lesen |